Vaccines conference provides an excellent multi-disciplinary forum for Vaccinologists, Immunologists, Scientists and Students in academia and industry to present and discuss their latest advances. In addition to peer-reviewed papers, the Vaccines event will present a wide range of presentations to inspire and facilitate all the Students, Scientists, Immunologists and Vaccinologists in their work.
This event will discuss various disciplines involved in learning about Vaccines & Immunology and its advances. It provides an explicit platform for presentations, distributes information, meets with current and potential scientists, makes a splash with new vaccines developments, and receive name recognition at this 2-days event.
The global vaccines market is one of the fastest growing segments and new predictions estimate the value of the market to reach between $48 billion and more than $70 billion over the next five to eight years.
According to a new report released, the value of the global human vaccines market is expected to grow from a $28.3 billion in 2015 to $72.5 billion in 2024. The projection would represent a compound annual growth rate (CAGR) of 11.2% from 2016 to 2024. Even though the dollar figure is large and growing, vaccines still only account 3% of the market share within the global pharmaceutical industry.
The vaccines market is highly competitive with the presence of several small and big companies. Some of the companies in the vaccines market are GlaxoSmithKline Plc. (U.K.), Pfizer, Inc. (U.S.), Merck & Co., Inc. (U.S.), CSL Limited (Australia), Emergent BioSolutions, Inc. (U.S.), Sanofi Pasteur SA (France), Johnson & Johnson (U.S.), MedImmune, LLC (U.S.), Astellas Pharma Inc. (Japan), Serum Institute of India (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), and Daiichi Sankyo Company, Limited (Japan).
Immunologic Research speaks to an interesting medium for the introduction, translation, and elucidation of complex logical information. Data is displayed as interpretive combination surveys, unique research articles, symposia, publications, and hypothetical expositions. The extent of scope stretches out to cell immunology, immunogenetics, sub-atomic and auxiliary immunology, immunoregulation and autoimmunity, immunopathology, tumor immunology, have safeguard and microbial resistance, including viral immunology, immunohematology, mucosal invulnerability, supplement, transplantation immunology, clinical immunology, neuroimmunology, immunoendocrinology, immunotoxicology, translational immunology, and history of immunology.
Pierre A. MORGON
|CEO & Founder, MRGN Advisors, Switzerland|